Samuel Lederman

Denosumab in Postmenopausal Women with Low Bone Mineral Density

Michael R. McClung, E. Michael Lewiecki, Stanley Cohen et al. · New England Journal of Medicine · 2006 · 1.2K citations · Full text

Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study

Samuel Lederman, Faith D Ottery, Antonio Cano et al. · The Lancet · 2023 · 219 citations

Phase 3, Gynecology, Menopausal Hormone Therapy +12

A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause

Graeme L. Fraser, Samuel Lederman, Arthur Waldbaum et al. · Menopause The Journal of The North American Menopause Society · 2020 · 112 citations · Full text

Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause

Genevieve Neal-Perry, Antonio Cano, Samuel Lederman et al. · Obstetrics and Gynecology · 2023 · 96 citations · Full text

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial

Erin A. Bohula, Benjamin M. Scirica, Silvio E. Inzucchi et al. · The Lancet · 2018 · 94 citations · Full text

Obesity, Metabolic Syndrome, Camellia-timi 61 +9